BNET Industries
Last Fiscal Year Sales:$1.2B
- Public
- US
Dow Jones Description
Founded in 1984, Sepracor was originally comprised of several diverse business units. In 1989, we embarked on a strategy of developing single isomers and active metabolites of many of the world's largest selling drugs, with the objective of developing our own proprietary pipeline of pharmaceutical products. Sepracor became a publicly traded corporation in 1991, and we subsequently divested our non-pharmaceutical business units into four different companies, retaining our core pharmaceutical business. Sepracor was built on the premise that chiral drugs could, in essence, be divided into two or more "parts" and that certain of these parts could be brought to the market as new medicines with the possibility for reduced side effects, greater potency or new indications. Sepracor was a pioneer in this area of drug development, identifying new, viable compounds. This strategy enabled Sepracor to establish itself initially by out-licensing the rights to a number of compounds to large, established pharmaceutical companies who developed and ultimately commercialized them. Some of these compounds have grown to become well-known brands in the pharmaceutical industry: ALLEGRA brand fexofenadine HCl, CLARINEX brand desloratadine and XYZAL /XUSALTM brand levocetirizine. ...
Number of Employees 2,400
Peer Companies
NAICS Code Pharmaceutical and Medicine Manufacturing: 3254
Recent Events
-
Sepracor's Lunesta patent extended
-
Sepracor CEO in line for $11M golden handshake
-
Data Missing On US Drug Labels
-
Sepracor deal closes, CEO in line for $11M
-
Standard & Poor's Announces Changes To U.S. Indices - Update
-
Dainippon Sumitomo To Acquire Sepracor For $2.6 Bln - Update
-
Dainippon to buy U.S. drug firm Sepracor for $2.6 billion
-
Japan firm acquires US drug maker Sepracor
-
Zacks Industry Rank Analysis Highlights: CVS Caremark, Life Technology, NuVasive, Inc., Sepracor and Gilead Sciences
-
Zacks Industry Rank Analysis Highlights: CVS Caremark, Life Technology, NuVasive, Inc.,...
-
Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of XyzalR Solution and...
News & Analysis
Filter by
patent and sepracor inc. - All News and Analysis
End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight
BNET
- 2009-06-13
Here's something that few noticed in Sepracor's Q1 2009 earnings announcement: The company's $155 million marketing deal for insomnia drug Lunesta/Lunivia with GlaxoSmithKline in Europe fell through. The collapse of the deal was predictable. I noted in July 2008 that GSK's subsequent $3.3 billion deal with Actelion...
Sepracor awarded patent for R-ondasentron, its eleventh U.S. patent for an improved form of an FDA-approved drug; Patent reinforces Sepracor's proprietary position in pharmaceutical marketplace
- 1995-12-14
MARLBOROUGH, Mass.--BUSINESS WIRE--Dec. 14, 1995--Sepracor Inc., (NASDAQ: SEPR), today announced that it has been granted its eleventh U.S. patent for an Improved Chemical Entity ICE , an improved form of an FDA-approved drug. The patent, No. 5,470,868, covers the use of R-ondansetron as an antiemetic.
PerSeptive Biosystems Files A New Lawsuit Against Pharmacia, Sepracor and BioSepra; New Patent Further Supports Perfusion Chromatography® Infringement Claims
- 1995-02-07
CAMBRIDGE, Mass--HealthWire--Feb. 7, 1995--PerSeptive Biosystems, Inc. (Nasdaq - NMS: PBIO) today announced it has filed a new lawsuit against Pharmacia (Nasdaq - NMS: PHARY) and certain of its subsidiaries, as well as Sepracor Inc., (Nasdaq - NMS: SEPR), and BioSepra Inc. (Nasdaq - NMS: BSEP) charging additional counts of infringement....
Sepracor Awarded Patent For S-Metoprolol, Its Ninth U.S. Patent For An Improved Form Of An Fda-Approved Drug
- 1995-02-01
MARLBOROUGH, Mass.--BUSINESS WIRE-- Feb. 1, 1995 -- Sepracor Inc., (NASDAQ: SEPR), today announced that it has been granted its ninth U.S. patent for an improved form of an FDA-approved drug. The patent, No. 5,362,757, covers the composition of matter and method of use of S-metoprolol, the single-isomer version of...
- 1
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
Glass Door
Sepracor
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express